Market Overview

UPDATE: Canaccord Genuity Upgrades Biogen Idec to Buy on BG-12 Early Launch

Share:
Related BIIB
Don't Get Too Excited About Biogen's Q4 Earnings
Orphan Drugs Among 2015's Top 10 Best-Selling Medications
Biotechnology: Can Trump Be A Catalyst? (Seeking Alpha)

Canaccord Genuity upgraded Biogen Idec (NASDAQ: BIIB) from Hold to Buy and raised the price target from $163.00 to $187.00.

Canaccord Genuity commented, "BIIB guidance implies now stronger confidence in the TEC launch. After new chats with KOLs and, importantly, community MDs, we have more confidence in the initial phase of launch due to growing levels of patient warehousing. We still see long-term value/blockbuster potential in TEC, Tysabri and the hemophilia franchise. We are raising our company-DCF based target to $187 based on higher 2013 estimates and lower discount rate."

Biogen Idec closed at $161.99 on Tuesday.

Latest Ratings for BIIB

DateFirmActionFromTo
Dec 2016Cantor FitzgeraldInitiates Coverage OnNeutral
Nov 2016MizuhoInitiates Coverage OnNeutral
Nov 2016Leerink SwannUpgradesMarket PerformOutperform

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Upgrades Analyst Ratings

 

Related Articles (BIIB)

View Comments and Join the Discussion!